Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension
Canadian Respiratory Journal · 2026-01 · 2026 (1)
DOI: 10.1155/carj/8046858 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Respiratory Journal, online erschienen am 08.04.2026. Verfasst von Yalei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn. Hauptthemen laut MEDLINE: Hypertension, Pulmonary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive, life‐threatening disease characterized by vascular remodeling, endothelial dysfunction, and chronic inflammation. Despite existing targeted therapies, long‐term outcomes remain poor, underscoring the need for more effective treatment. This review summarizes recent advancements in PAH therapy, emphasizing the integration of conventional medicine of the key pathways with nanoparticle‐mediated drug delivery systems (nano‐DDS), transforming growth factor beta/bone morphogenetic protein receptor type II, tyrosine kinase–based interventions, immunotherapies targeting inflammation and immune imbalance, and emerging molecular targets, including NOTCH3/HES‐5 and E‐selectin. Nano‐DDS has improved drug bioavailability and targeting, opening new therapeutic possibilities. This article also discusses innovative approaches, such as endothelial‐like progenitor cell–based cell therapy and the ETRQβ‐002 vaccine. Future advancements in PAH treatment may result from the integration of conventional drugs, nanotechnology, and immunotherapy through multidisciplinary efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.
- Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.
- Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China…
- Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China, meb.gov.tr.
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China, rmhospital.com.
ORCID-Profile: Yalei Wang, Jiacheng Wu, Qian Ma, Hao Chen, Erha Lama, Yulu Yang, Jianwu Huang, Changhu Liu, Xiaofei Ni, Zhihua Qiu, Zihua Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Wu, J., Ma, Q., Chen, H., Lama, E., Yang, Y., Huang, J., Liu, C., Ni, X., Qiu, Z., & Zhou, Z. (2026). Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension. Canadian Respiratory Journal, 2026(1). https://doi.org/10.1155/carj/8046858
Vancouver
Wang Y, Wu J, Ma Q, Chen H, Lama E, Yang Y, et al. Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension. Canadian Respiratory Journal. 2026;2026(1). doi:10.1155/carj/8046858
BibTeX
@article{Wang2026,
author = {Wang, Yalei and Wu, Jiacheng and Ma, Qian and Chen, Hao and Lama, Erha and Yang, Yulu and Huang, Jianwu and Liu, Changhu and Ni, Xiaofei and Qiu, Zhihua and Zhou, Zihua},
title = {Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension},
journal = {Canadian Respiratory Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/carj/8046858}
}
EUVIMED